Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.90 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.90 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.90 |
| ▸ | PGR | P06401 | 1/20 | 0.90 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.90 |
| ▸ | F7 | P08709 | 3/20 | 0.62 |
| ▸ | F3 | P13726 | 3/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.62 |
| ▸ | PPARG | P37231 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | PPARD | Q03181 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21670446 | 1.00 | ALDH1A1 (0.97) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL21670445 | 1.00 | ALDH1A1 (0.97) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL12654675 | 0.98 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL4814473 | 0.98 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL28523361 | 0.98 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL12654374 | 0.98 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL4814472 | 0.98 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL9905970 | 0.98 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL31398205 | 0.98 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL14458380 | 0.98 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113365637-A | Compositions and methods for treating liver disorders | 维京治疗公司 | 2021-09-07 | — | — | CN | claimed |
| EP-3196280-B1 | COMPOSITION CONTAINING EICOSAPENTAENOIC ACID ALKYL ESTER, AND METHOD FOR PRODUCING SAME | NISSUI CORP (JP) | 2026-02-25 | — | — | EP | disclosed |
| EP-4619001-A1 | ORAL DOSAGE FORMS FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME | Viking Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250134913-A1 | ORAL DOSAGE FORMS OF TRβ AGONIST VK2809 FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME | VIKING THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4482470-A1 | CYCLIC PHOSPHONATE COMPOSITION AND PREPARATION METHOD THEREOF | Gannex Pharma Co., Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| EP-4479062-A1 | FORMES POSOLOGIQUES ORALES DE L'AGONISTE DE TRß, VK2809, POUR LE TRAITEMENT DE TROUBLES HÉPATIQUES, ET PROCÉDÉS DE PRÉPARATION DE CELLES-CI | Viking Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-20240325417-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | GANNEX PHARMA CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| US-20240293385-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | GANNEX PHARMA CO., LTD. (CN) | 2024-09-05 | — | — | US | disclosed |
| CN-118339292-A | Antisense inhibitors of MIR17HG precursor RNAs as cancer therapeutics | 丹娜-法伯癌症研究院 | 2024-07-12 | — | — | CN | disclosed |
| US-20240207290-A1 | CYCLIC PHOSPHONATE COMPOSITION AND PREPARATION METHOD THEREOF | GANNEX PHARMA CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| WO-2024107862-A1 | ORAL DOSAGE FORMS FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME | VIKING THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-4366696-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | Gannex Pharma Co., Ltd. (CN) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023163795-A1 | CYCLIC PHOSPHONATE COMPOSITION AND PREPARATION METHOD THEREOF | GANNEX PHARMA CO., LTD. (CN) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023158616-A1 | ORAL DOSAGE FORMS OF TRβ AGONIST VK2809 FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME | VIKING THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| US-11648229-B2 | Composition containing eicosapentaenoic acid alkyl ester, and method for producing same | NIPPON SUISAN KAISHA, LTD. (JP) | 2023-05-16 | — | — | US | disclosed |
| WO-2023280150-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | GANNEX PHARMA CO., LTD. (CN) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023280152-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | GANNEX PHARMA CO., LTD. (CN) | 2023-01-12 | — | — | WO | disclosed |
| CN-115350493-A | Method for separating and purifying eicosapentaenoic acid ethyl ester in fish oil and rectifying device | 江苏海莱康生物科技有限公司 | 2022-11-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207290-A1 | CYCLIC PHOSPHONATE COMPOSITION AND PREPARATION METHOD THEREOF | PHOSPHO1, PIK3CA, PPA1 | ALDH1A1 1675/4885CYP3A4 925/4885ALOX15 1122/4885 |
| US-20240325417-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | PYGL, GYS2, OAT | ALDH1A1 373/4885CYP3A4 860/4885ALOX15 939/4885 |
| US-20250134913-A1 | ORAL DOSAGE FORMS OF TRβ AGONIST VK2809 FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME | AVPR1A, THRA, PRLHR | ALDH1A1 2437/4885CYP3A4 69/4885ALOX15 3422/4885 |
| US-20240293385-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | SLC10A1, OAT, GOT2 | ALDH1A1 406/4885CYP3A4 420/4885ALOX15 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.